Full-Time

Senior Clinical Regulatory Specialist

Posted on 8/19/2026

Iterative Health

Iterative Health

51-200 employees

AI-powered polyp detection for colorectal cancer

No salary listed

Cambridge, MA, USA + 2 more

More locations: Southlake, TX, USA | New York, NY, USA

Hybrid

Two days on-site per week required in New York City, Southlake, or Boston.

Category
Legal & Compliance (1)
Required Skills
FDA Regulations

Get referred to Iterative Health

See people who can refer or advise you

Requirements
  • Four or more years of relevant experience in clinical research, clinical regulatory, and/or research operations supporting industry-sponsored clinical trials.
  • Strong experience supporting Phase 2–4 sponsor-initiated clinical trials, ideally in a site-facing regulatory capacity.
  • Previous experience as a Clinical Research Coordinator, Regulatory Coordinator or Specialist, or another clinical research role with significant responsibility for regulatory activities.
  • Strong working knowledge of Good Clinical Practice, applicable Food and Drug Administration regulations and guidance, Institutional Review Board processes, and clinical research standard operating procedures.
  • Demonstrated experience independently managing regulatory activities across multiple studies and/or research sites.
  • Experience reviewing regulatory documentation and submissions for quality, completeness, and compliance.
  • Ability to manage multiple studies, sites, deadlines, and competing priorities through strong organizational, time-management, and prioritization skills.
  • Exceptional attention to detail and commitment to maintaining accurate, complete, and inspection-ready documentation.
  • Strong written and verbal communication skills and ability to build effective relationships with site staff, sponsors, contract research organizations, Institutional Review Boards, and internal stakeholders.
  • Ability to work independently, exercise sound judgment, and take ownership of complex regulatory activities.
Responsibilities
  • Facilitate and oversee regulatory activities across study start-up, site activation, maintenance, and closeout for Phase 2–4 industry-sponsored clinical trials.
  • Provide regulatory guidance and oversight to research sites across multiple studies, ensuring timely and accurate completion of regulatory requirements.
  • Review and quality-control regulatory documentation and submissions for completeness, accuracy, consistency, and compliance, identifying gaps and driving resolution.
  • Manage complex regulatory activities and submissions, including Institutional Review Board applications, amendments, continuing reviews, safety reports, unexpected events, and other study-specific regulatory requirements.
  • Monitor regulatory timelines, approvals, expirations, and outstanding requirements to identify potential delays or compliance risks.
  • Identify, assess, and escalate regulatory risks and compliance issues, partnering with sites, sponsors, contract research organizations, and internal stakeholders to implement corrective and preventive actions.
  • Serve as a subject matter resource for site teams and internal stakeholders on regulatory requirements, study-specific expectations, and best practices.
  • Ensure regulatory documentation and processes remain consistent, compliant, and inspection-ready across the research network.
  • Maintain accurate regulatory records, trackers, and documentation within applicable clinical research and regulatory systems.
  • Serve as a senior regulatory point of contact for assigned research sites and act as a liaison between sites, sponsors, contract research organizations, Institutional Review Boards, and internal stakeholders.
  • Provide guidance and mentorship to site teams on regulatory processes, documentation requirements, compliance expectations, and study-specific requirements.
  • Partner with sites to identify regulatory challenges, develop solutions, and drive timely resolution of outstanding issues.
  • Participate in monitor visits, quality assurance and quality-control projects, site-level audits, and other quality activities, supporting inspection readiness and remediation of findings.
  • Support sites in preparing for regulatory inspections and audits, including identifying documentation gaps and coordinating timely remediation.
  • Drive continuous improvement of regulatory processes, tools, and workflows across the clinical research network.
  • Identify opportunities to improve efficiency, standardization, quality, and compliance across regulatory operations.
  • Develop and maintain regulatory resources, templates, trackers, standard operating procedures, and training materials to support consistent execution across sites.
  • Support training, mentorship, and knowledge sharing for Clinical Regulatory Specialists and research site teams.
  • Contribute to the development and implementation of network-wide regulatory strategies, processes, and best practices.
  • Partner cross-functionally to identify trends, recurring issues, and opportunities to improve the site and study experience.
  • Support implementation and adoption of new regulatory systems, tools, and processes as the clinical research network scales.
  • Perform related duties as requested.
Desired Qualifications
  • Experience mentoring, training, or providing guidance to less experienced team members.
  • Experience with a Clinical Trial Management System, electronic regulatory platform, electronic source documentation, or other clinical research technology.

Iterative Health develops and deploys AI-powered tools for gastrointestinal (GI) care. Its main product is SKOUT®, an FDA-cleared device that helps doctors find adenomas (polyps) during GI procedures, supporting clinical judgment rather than replacing it. The company also offers AI-enabled documentation and data standardization technologies to improve the quality of patient care and to streamline clinical trials, enabling consistent reporting across institutions. By combining AI image analysis, data-driven insights, and streamlined research workflows, Iterative Health aims to improve colorectal cancer prevention and diagnosis and to extend high-quality GI care to underserved populations around the world.

Company Size

51-200

Company Stage

Series C

Total Funding

$262.2M

Headquarters

Boston, Massachusetts

Founded

2017

Get referred to Iterative Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 8, 2026 GANJ partnership adds New Jersey GI research sites and IBD volume.
  • August 11, 2026 Mount Sinai advisor Samin Sharma deepens cardiology credibility for sponsors.
  • May 14, 2026 NextStage site acquisitions and April financing accelerate cardiology and obesity growth.

What critics are saying

  • Sponsor concentration risks hit quickly if cardiology or obesity trials underperform in 2026.
  • Community-network expansion increases quality-control failures; one site scandal can damage the whole brand.
  • If payment from pharma stalls, Iterative Health's capital-heavy network model becomes existentially fragile.

What makes Iterative Health unique

  • Iterative Health embeds research inside community GI practices, not standalone academic centers.
  • Its April 30, 2026 Series C backs a multispecialty network across four continents.
  • SKOUT gives colonoscopy teams real-time adenoma detection, strengthening the GI workflow.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Vision/Dental/ Medical Insurance

Life/Disability Insurance

Parental Leave

Stock Options

Flexible Work Hours

Unlimited Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-1%

2 year growth

-6%
Associated Press
Aug 11th, 2026
Iterative Health appoints Mount Sinai's Dr Samin K. Sharma as honorary chair of interventional cardiology

Iterative Health has appointed Dr Samin K. Sharma as scientific advisor and honorary chair of interventional cardiology. Dr Sharma is director of the Cardiovascular Clinical Institute at Mount Sinai Hospital and director of interventional cardiology at Mount Sinai Health System. Dr Sharma has over 30 years of experience and has authored more than 350 peer-reviewed articles. He pioneered the use of the Rotablator technique for complex coronary blockages. The appointment follows Iterative Health's recent US site network expansion, including acquiring cardiology research sites from NextStage Clinical Research and partnering with US Heart & Vascular. The company's network spans more than 100 sites across three continents in GI, hepatology, obesity, and cardiology research.

Business Wire
Aug 11th, 2026
Iterative Health appoints Dr. Samin K. Sharma at Mount Sinai Hospital as honorary chair of Interventional Cardiology.

Iterative Health appoints Dr. Samin K. Sharma at Mount Sinai Hospital as honorary chair of Interventional Cardiology. CAMBRIDGE, Mass.-(BUSINESS WIRE)-Iterative Health, a healthcare technology and services company powering the acceleration of clinical research, today announced the appointment of Samin K. Sharma, MD, FACC, MSCAI, Director of the Cardiovascular Clinical Institute at The Mount Sinai Hospital, as a scientific advisor and honorary chair of Interventional Cardiology. In this role, Dr. Sharma brings best-in-class clinical and scientific leadership from one of the foremost academic medical centers to advance the company's cardiology strategy. "Dr. Sharma is a world-renowned physician recognized for his clinical judgment, commitment to patient-centered care, and contributions to the field," said Jonathan Ng, founder and CEO of Iterative Health. "His experience will help strengthen our therapeutic expertise, protocol and trial design, and scientific publications, ultimately helping our sites move studies forward with the excellence and rigor sponsors expect." Dr. Sharma is director of the S.P. and Seema Lohia Cardiovascular Clinical Institute and director of interventional cardiology at Mount Sinai Health System, where he also serves as president of the Mount Sinai Heart Network. With more than 30 years of experience, he is one of the most awarded cardiologists for his contributions to medical science. He is also credited with pioneering the use of the Rotablator technique for complex, calcified coronary blockages, has authored more than 350 peer-reviewed articles, and sits on the editorial boards of several cardiology journals. Dr. Sharma is passionate about medical education, mentoring fellows and experienced cardiologists alike through innovative teaching methods, including symposiums and live-broadcast cases that reach thousands. "There's a real gap between what a trial protocol asks for and what's actually workable at the bedside, and it can cost a study valuable time," said Dr. Sharma. "Iterative Health has built a research network around closing that gap, and it's an honor to help the company strengthen its impact in advancing cardiology research." The appointment follows Iterative Health's recent US site network expansion, including the acquisition of established cardiology research sites from NextStage Clinical Research and a strategic partnership with US Heart & Vascular. The company's network spans more than 100 high-performing sites across three continents in GI, hepatology, obesity, and cardiology research. About Iterative Health Iterative Health is a healthcare technology and services company powering the acceleration of clinical research to transform patient outcomes. By combining deep expertise in clinical trials with cutting-edge AI, we empower research teams and study sponsors to expand and expedite access to novel therapeutics for patients in need. The company has headquarters in Cambridge, Massachusetts, and New York, New York. For more information, visit www.iterative.health and follow us on LinkedIn for the latest company updates. Contacts. Media Contact Iterative Health: Andrea Sampson President/CEO, Sampson Public Relations Group [email protected] More News From Iterative Health CAMBRIDGE, Mass.-( BUSINESS WIRE )-Iterative Health and Gastroenterology Associates of New Jersey partnered to expand access to GI clinical research in New Jersey... CAMBRIDGE, Mass.-( BUSINESS WIRE )-Iterative Health announced the acquisition of three cardiology sites from NextStage Clinical Research... CAMBRIDGE, Mass.-( BUSINESS WIRE )-Iterative Health announced the presentation of updated scientific research at Digestive Disease Week (DDW) 2026...

Associated Press
Jul 8th, 2026
Iterative Health partners with GANJ to expand GI clinical research across New Jersey

Iterative Health has partnered with Gastroenterology Associates of New Jersey (GANJ) to expand clinical research access across New Jersey. The collaboration establishes two research sites in Toms River and Clifton, joining Iterative Health's network of over 110 sites globally. GANJ operates 28 locations across New Jersey with more than 60 healthcare professionals. The partnership integrates clinical research into community GI care, leveraging New Jersey's population of over 9.5 million residents and its ethnic diversity. Iterative Health will serve as GANJ's research partner, combining the practice's clinical expertise with its AI-powered technology and operational model. The collaboration focuses particularly on inflammatory bowel disease, with GANJ recently establishing a Comprehensive IBD Care Centre. Additional research sites are under discussion across GANJ's broader provider network. Iterative Health operates the largest community-embedded research site network in the US for GI, hepatology, obesity, and cardiology clinical development.

Planet First Partners
Jun 30th, 2026
Iterative Health raises $77M Series C to accelerate clinical trials with AI-powered research network

Planet First Partners has invested in Iterative Health, a healthcare technology company focused on accelerating clinical research. The investment follows Iterative Health's recent $77 million Series C funding round led by Intrepid Growth Partners and Google Ventures, with participation from EDBI, a family office, Insight Partners, and Obvious Ventures. Iterative Health operates a clinical research network spanning over 100 sites across North America, Europe, India, and Australia. The company uses AI and centralised operations to improve trial efficiency, achieving twice faster site activation and three times higher patient enrolment compared to industry standards. The Series C funds will support expansion into cardiology and obesity research, building on the company's existing focus on gastroenterology and hepatology. Iterative Health partners with over 40 pharmaceutical, biotech, and CRO organisations.

Business Wire
May 14th, 2026
Iterative Health acquires 3 cardiology sites from NextStage Clinical Research in Texas

Iterative Health, a healthcare technology and services company, has acquired three cardiology research sites in Texas from NextStage Clinical Research. The sites, located in Beaumont, Port Arthur and Waco, bring experienced research teams and established cardiovascular trial operations. The acquisition expands Iterative Health's cardiology footprint as part of its strategy to embed clinical research within community care settings. The company operates over 100 sites across three continents, supported by a 250-person team and proprietary AI tools for patient recruitment and trial design. Cardiovascular disease affects nearly half of US adults, yet clinical trial access remains uneven. The addition strengthens Iterative Health's capabilities across therapeutic areas including gastroenterology, hepatology and obesity, whilst providing patients access to innovative cardiovascular therapies and devices.